Investor Presentation Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Company Update Investor Presentation - Q4 FY 25-26 Investor Presentation - Q4 FY 25-26
General Updates The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company. The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company. The Board of Directors, at its meeting held today, has approved the t
General Updates The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company. The Board of Directors, at its meeting held today, has approved the transfer of the Company's Nebulizer brands/IP portfolio to Glenmark Healthcare Limited ( GHL ), a wholly owned subsidiary of the Company. The Board of Directors, at its meeting held today, has approved the t
Corp. Action The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs.
Corp. Action The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs.
Corp. Action The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at the ensuing Annual General Meeting. The Board has recommended dividend of Rs.
Dividend Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Fina
Dividend Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Fina
Dividend Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 2.5 per equity share. Glenmark Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Fina
Outcome of Board Meeting Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Outcome of Board Meeting Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NSE & BSE filings, quarterly results, insider trades, and smart volume alerts — delivered on WhatsApp or Telegram. No separate app to install.
Need more? Pro tracks up to 500 companies with preferential issue alerts.
No credit card required. Connect WhatsApp or Telegram in minutes.